2910858-34-1

2910858-34-1 structure
2910858-34-1 structure
  • Name: Antiproliferative agent-34
  • Chemical Name: Antiproliferative agent-34
  • CAS Number: 2910858-34-1
  • Molecular Formula: C27H27N7O5
  • Molecular Weight: 529.55
  • Catalog: Signaling Pathways JAK/STAT Signaling EGFR
  • Create Date: 2024-04-08 09:26:10
  • Modify Date: 2024-04-08 09:26:10
  • Antiproliferative agent-34 (Compound A14) is a multi-target kinase inhibitor, with an IC50 of 177 nM and 1567 nM for EGFR L858R/T790M and EGFR WT. Antiproliferative agent-34 also inhibits JAK2, ROS1, FLT3, FLT4, PDGFRα with IC50 of 30.93, 106.90, 108.00, 226.60, 42.53 nM. Antiproliferative agent-34 inhibits H1975 and HCC827 cells proliferation with IC50 values below 40 nM under normoxic condition, and the anti-proliferation potency achieves 4–6-fold improvement (IC50 values < 10 nM) under hypoxic condition[1].

Name Antiproliferative agent-34
Description Antiproliferative agent-34 (Compound A14) is a multi-target kinase inhibitor, with an IC50 of 177 nM and 1567 nM for EGFR L858R/T790M and EGFR WT. Antiproliferative agent-34 also inhibits JAK2, ROS1, FLT3, FLT4, PDGFRα with IC50 of 30.93, 106.90, 108.00, 226.60, 42.53 nM. Antiproliferative agent-34 inhibits H1975 and HCC827 cells proliferation with IC50 values below 40 nM under normoxic condition, and the anti-proliferation potency achieves 4–6-fold improvement (IC50 values < 10 nM) under hypoxic condition[1].
Related Catalog
Target

177, 30.93, 106.90, 108.00, 226.60, 42.53 nM for EGFR L858R/T790M, JAK2, ROS1, FLT3, FLT4, PDGFRα respectively[1]

References

[1]. Jia T, et al. Discovery of novel hypoxia-activated, nitroimidazole constructed multi-target kinase inhibitors on the basis of AZD9291 for the treatment of human lung cancer. Bioorg Med Chem. 2023 Aug 15;91:117384.  

Molecular Formula C27H27N7O5
Molecular Weight 529.55
The content on this webpage is sourced from various professional data sources. If you have any questions or concerns regarding the content, please feel free to contact service1@chemsrc.com.